Who Owns Cathay Biotech Company?

Cathay Biotech Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Cathay Biotech?

Understanding a company's ownership is key to grasping its strategy and accountability. Cathay Biotech Inc., a leader in synthetic biology for bio-based materials, went public on the STAR Market of the Shanghai Stock Exchange on August 12, 2020. This IPO broadened its investor base while solidifying the founders' influence.

Founded in 2000 and headquartered in Shanghai's Zhangjiang Hi-Tech Park, Cathay Biotech pioneers bio-manufacturing for sustainable chemical industry solutions. The company develops and produces high-performance bio-based products like long-chain dibasic acids, essential for polymers and coatings. As of August 19, 2025, its market capitalization reached approximately $5.11 billion USD (35.37 billion CNY).

The ownership journey of Cathay Biotech, from its inception to its current structure, reveals significant shifts. Early backers played a crucial role, followed by the impact of its public offering. Examining major stakeholders, institutional and individual, alongside board dynamics and voting power, provides insight into the company's trajectory. This includes the market's reception of products like those detailed in the Cathay Biotech PESTEL Analysis.

Cathay Biotech Inc. was established in Shanghai, China, in the year 2000, focusing on innovative bio-manufacturing technologies. The primary ownership and ongoing control of the company have been consistently linked to the family of Xiu Cai Liu, who holds the position of President. While specific initial equity distributions among founders are not publicly disclosed, the Liu family's sustained influence, often through various entities, highlights their crucial role in guiding the company's early trajectory and ownership structure.

Founding Family's Control

The Liu family, led by President Xiu Cai Liu, has maintained a central role in Cathay Biotech's ownership since its inception in 2000. This enduring influence shapes the company's strategic direction and corporate governance.

Early External Investment

In its early stages, Cathay Biotech secured significant external funding to support its expansion. The company successfully raised a total of $213 million across three funding rounds.

Key Funding Milestones

The first funding round, a Series A, occurred in May 2006, bringing in $26 million. A subsequent private equity round on December 14, 2015, provided an additional $135 million.

Notable Early Investors

Prominent institutional investors such as Goldman Sachs and HBM Partners participated in the company's early funding rounds. Goldman Sachs was involved in the Series B round in December 2006, while HBM Partners participated in the 2015 private equity round.

Consolidated Control

Despite the introduction of external shareholders through these investments, overall control of Cathay Biotech has remained largely consolidated within the founding family's sphere of influence. This suggests a deliberate strategy to maintain long-term vision alignment.

Strategic Ownership Approach

The company's approach to ownership distribution appears strategic, ensuring that the founders' long-term objectives for developing sustainable biotechnology are effectively supported and maintained.

The early ownership structure of Cathay Biotech Inc. was characterized by the foundational control of the Xiu Cai Liu family, who established the company in 2000. This family's influence has been a consistent factor in the company's development and strategic direction. While external investments were crucial for growth, the primary ownership and operational control remained largely within the family's purview, indicating a deliberate strategy to safeguard their vision for sustainable biotechnology advancements. Understanding the Mission, Vision & Core Values of Cathay Biotech provides further context to their long-term ownership strategy.

Founders and Early Ownership Overview

Cathay Biotech's journey began in 2000, with the Liu family, led by Xiu Cai Liu, at its core of ownership and leadership. Early external funding rounds, totaling $213 million, brought in institutional investors like Goldman Sachs and HBM Partners, yet the founding family maintained consolidated control.

• Founded in 2000 in Shanghai, China.
• Primary ownership and control by the Xiu Cai Liu family.
• Total early funding of $213 million across three rounds.
• Key investors included Goldman Sachs and HBM Partners.
• Founding family maintained consolidated control despite external investment.

Cathay Biotech SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Cathay Biotech Inc.'s ownership landscape has seen significant shifts, most notably following its listing on the STAR Market of the Shanghai Stock Exchange on August 12, 2020. This event, with the stock code 688065.SH and an IPO price of RMB 133.45, initially valued the company at over RMB 80 billion, setting the stage for subsequent changes in its shareholder base.

The ownership structure of Cathay Biotech Inc. has evolved significantly, with the Xiu Cai Liu family and associated entities consolidating their control. A key development was the transfer of a 20.00% stake from Cathay Industrial Biotech Ltd. to Shanghai Yaoxiu Biotechnology Partnership (Limited Partnership) on December 31, 2024. This transaction positioned Shanghai Yaoxiu as the new controlling shareholder, holding 35.29% post-issuance. As of March 30, 2025, the actual controller, Xiu Cai Liu family, and their controlled enterprises collectively increased their voting rights to 44.04%, reinforcing their influence over the company's strategic direction and governance.

Key Stakeholders in Cathay Biotech

Understanding Cathay Biotech's ownership is crucial for grasping its corporate structure and strategic trajectory. The company's major shareholders play a vital role in its ongoing development.

• Shanghai Yaoxiu Biotechnology Partnership (Limited Partnership) is the primary controlling shareholder.
• The Xiu Cai Liu family maintains significant indirect control through employee shareholding platforms.
• Institutional investors like Shanxi State-owned Capital Operation Co., Ltd. and HBM Partners Ltd. are also key stakeholders.
• Cathay Industrial Biotech, Ltd. remains a notable non-controlling shareholder.
• The company's public listing on the STAR Market provides transparency into its ownership breakdown, which is essential for those interested in the Target Market of Cathay Biotech.

Cathay Biotech PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The board of directors at Cathay Biotech Inc. operates under a governance framework where Xiu Cai Liu, serving as President, holds significant influence as the de facto controller. While specific details on all board members and their affiliations beyond major shareholders are not extensively publicized, recent shifts in ownership clearly indicate that the board's strategic direction is closely aligned with the controlling family's interests.

The company's voting power is predominantly shaped by its shareholding distribution. As of April 3, 2025, the Xiu Cai Liu family, through direct holdings and associated entities, commands a substantial 44.04% of the voting rights. This concentration of power, further solidified by recent A share issuances, grants the Liu family considerable sway in critical decision-making processes, including director appointments and senior management changes, thereby maintaining the company's de facto control. Cathay Biotech has expressed its commitment to robust corporate governance and has proposed the addition of a Vice Chairman to its board, signaling ongoing efforts to enhance its governance structure. There have been no recent public reports of significant challenges to this established control from proxy battles or activist investors.

Cathay Biotech's Governance and Ownership

Understanding Cathay Biotech's ownership structure is key to grasping its corporate governance. The Xiu Cai Liu family's significant voting power ensures their continued influence over the company's direction.

• Xiu Cai Liu is the President and de facto controller.
• The Liu family holds 44.04% of voting rights as of April 3, 2025.
• Recent A share issuances have consolidated family control.
• The company is working to refine its corporate governance framework.
• No major challenges to established control have been reported recently.

Cathay Biotech Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments have significantly reshaped Cathay Biotech's ownership landscape. A substantial share issuance in March 2025, aimed at raising capital, also led to a notable increase in the voting rights held by the Xiu Cai Liu family and their associated entities, solidifying their control.

The company's strategic financial management includes an ongoing equity buyback initiative, demonstrating a commitment to employee incentives and share capital optimization. This proactive approach to capital management, coupled with strong financial performance and expansion in bio-based materials, positions the company for continued growth and innovation within the sustainable chemicals sector.

Ownership Consolidation

The Xiu Cai Liu family's control has been strengthened through a recent share issuance, increasing their voting power. Shanghai Yaoxiu Biotechnology Partnership is now the primary controlling entity.

Capital Management Strategy

An equity buyback program is in place to support employee stock plans. This reflects a strategy to align employee interests with company performance.

Financial Performance and Growth Drivers

In 2024, revenue saw a significant increase of 39.91%, reaching 2.958 billion yuan. Growth is fueled by strong sales of long-chain dicarboxylic acids and new bio-based materials.

Innovation and Market Expansion

The company is expanding production capacity for bio-based chemicals and developing new sustainable product lines. Significant R&D investment, totaling 150 million RMB in 2023, supports these efforts. For more on the company's journey, see the Brief History of Cathay Biotech.

Cathay Biotech Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔